DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2010/0016395 A1 Benozzi (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2010/0016395 A1 Benozzi (43) Pub US 2010.001 6395A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0016395 A1 Benozzi (43) Pub. Date: Jan. 21, 2010 (54) OPHTHALMIC COMPOSITIONS OF (86). PCT No.: PCT/B07/03780 PARASYMPATHETIC STIMULANTS AND ANTI-NFLAMMATORES FOR USE IN THE S371 (c)(1), TREATMENT OF PRESBYOPA (2), (4) Date: Aug. 10, 2009 (30) Foreign Application Priority Data (76) Inventor: Jorge Luis Benozzi, Buenos Aires (AR) Dec. 18, 2006 (EP) .................................. O6026169.0 Publication Classification Correspondence Address: (51) Int. Cl. YOUNG & THOMPSON A6II 3/478 (2006.01) 209 Madison Street, Suite 500 A6IP27/02 (2006.01) Alexandria, VA 22314 (US) (52) U.S. Cl. ........................................................ 514/397 (57) ABSTRACT (21) Appl. No.: 12/519,910 Ophthalmic compositions for the treatment of presbyopia, including combinations of parasympathomimetics and non (22) PCT Filed: Dec. 6, 2007 steroidal anti-inflammatories. US 2010/001 6395 A1 Jan. 21, 2010 OPHTHALMC COMPOSITIONS OF 0013 The parasympathomimetics present in the combina PARASYMPATHETIC STIMULANTS AND tions of the invention act on the contraction/relaxation ANTI-NFLAMMATORIES FOR USE IN THE strength of the ciliary muscle thus keeping accommodation TREATMENT OF PRESBYOPA levels stable, while NSAIDs preserve such action in time, preventing those physiological degenerations typically occurring in time with presbyopic Subjects. The combinations 0001. The present invention relates to ophthalmic compo of the invention prevent any histological and physical alter sitions comprising parasympathetic stimulants and non-ste ations (fibrosis and rigidity) in the ciliary muscle-Zonula roidal anti-inflammatories for use in the treatment of pres complex. byopia. 0014. The present invention provides successful, stable results in emmetropic and hypermetropic patients for at least PRIOR ART five years; on the other hand, the invention is unsuccessful when shape modification of the lens is prevented by its rigid 0002 Presbiopia, a defect in accommodation, has tradi ity. tionally been treated with the use of corrective lens. 00.15 More particularly, the present invention relates to 0003. In recent years, surgery methods such as scleral ophthalmic compositions of pilocarpine and a NSAID for use expansion band, anterior ciliary Sclerotomy, multifocal in the treatment of presbyopia. intraocular lenses or laser ablation of sclera retrolimbare 0016. According to a preferred aspect of the invention, (U.S. Pat. Nos. 6,263,879 and 6,258,082) have been sug pilocarpine is in form of its hydrochloride and the NSAID is gested to correct presbyopia. All of such techniques are, how diclofenac sodium. ever, controversial, as they do not solve the mechanical prob 0017. The compositions of the invention will contain the lem of accommodation (Mathews S., Scleral Expansion parasympathomimetic agent in amounts ranging from 0.5% Surgery does not Restore Accommodation in Human Pres to 4% and the NSAID in amounts ranging from 0.01 mg. to byopia. Ophthalmology 1999; 106: 873-877). 0.1 mg. 0004 Publications concerning the treatment of presbyo 0018. According to a preferred aspect of the invention, the pia do not take into account Such mechanism and aim at a compositions will contain pilocarpine hydrochloride in con Surgical correction of near vision. centrations ranging from 1% to 2% and diclofenac sodium in 0005 Lin-Kadambi Suggest sympathetic and parasympa amounts ranging from 0.1% to 0.5%. thetic stimulation with adrenergic and cholinergic drugs to (0019. The ophthalmic compositions will be suitably for pharmacologically assist stabilization of the Surgical results. mulated for the topical administration, according to well Pharmacological treatment to treat accommodation in man known procedure and techniques, such as those described in has been reported in previous articles. “Remington's Pharmaceutical Handbook’. 18th edition 0006. According to Rosenfield, treatment with an alpha (June 1995), Mack Publishing Co., N.Y., USA, using conven adrenergic antagonist induced an increase in accommodative tional additives well known in the pharmaceutical technique. amplitude of 1.5D. Said action, however, only lasts two hours Example of said additives are isotonic agents, such as propy (Rosenfield M. The influence of Alpha-adrenergic-agents on lene glycol, Sodium chloride, potassium chloride, glycerine, tonic accommodation. Current Eye Research, Vol. 9, 3, 1990, Sorbitol, mannitol, and the like; buffers, such as boric, phos pp. 267-272). phoric, acetic, carbonic, citric acids, and the like; stabilizers, 0007 According to Nyberg, van Alphen et al., therapy Such as ethylenediaminetetraacetic acids, Sodium hydrogen with alpha-adrenergic-agents was not satisfactory in presby Sulphite, and the like; pH agents, such as citric, phosphoric, opic patients. hydrochloric, acetic acids, sodium or potassium hydroxide, 0008 Nolan (U.S. Pat. No. 6,273,092) reports that topical sodium carbonate or bicarbonate, and the like; solubilizers, application of acetylcholine and physostygmine to presby Such as polysorbate, polyethylene glycol, propylene glycol, opic patient gives poor results and does not solve blurred macrogol 4000, and the like; thickening and dispersing distant vision. agents, such as cellulose derivatives, sodium alginate, poly vinyl alcohol, carboxyvinylpolymer, polyvinyl pyrrolidone, DISCLOSURE OF THE INVENTION and the like. 0020. The results of the pharmacological experimentation 0009. The present invention relates to the pharmacological with the compositions of the invention are reported the fol treatment of presbyopia, without Surgical intervention. lowing. 0010. It has in fact been found that alterations of visual 0021 Materials and Methods accommodation can be treated by stimulating the sympa 0022 100 Presbiopic patients of both sexes, of age 40 to thetic innervation which induces accommodation for near 65, were treated with the compositions of the invention. vision by use of parasympathomimetics and that said results Exclusion criteria concerned patients with myopia or astig can be maintained in time by treatment with non-steroidal matism higher than 1 dioptre, and hypermetropia greater than anti-inflammatories (NSAIDs). 3 dioptres as well as those with corneal, lens and vitreous 0011. According to the invention, non-steroidal anti-in opacitis, and chronic general pathologies. flammatories can be selected from the group consisting of diclofenac, ketorolac, bromfenac, flurbiprofen, Suprofen, 0023) 4 Different groups of presbyopic population were pranoprofen, oxyphenbutaZone, bendaZac, indomethacin. differentiated: 0012. Therefore, the present invention relates to ophtalmic 0024 Group 1: Pure presbyopics compositions comprising combinations of parasympathomi 0025 Group 2: Presbyopics with hypermetropia metics and non-steroidal anti-inflammatories for the treat 0026 Group 3: Presbyopics with phorias ment of presbyopia. 0027 Group 4: Presbyopics with glaucoma US 2010/001 6395 A1 Jan. 21, 2010 0028 Patients of all groups were treated with eye drops of 0049) 10 patients have been under treatment for 6 years different concentrations and combinations of medicaments 0050 20 patients have been under treatment for 5 years acting on the ocular sympathetic innervation. 0051 30 patients have been under treatment for 4 years 0029 Pure presbyopic patients (Group 1) were topically 0.052 40 patients have been under treatment for 3 years treated with 1% pilocarpine hydrochloride--0.5% diclofenac 0053 80 patients have been under treatment for 2 years Sodium, at 6hr intervals during the daily hours; treatment was 0054 96 patients have been under treatment for 1 year. Suspended at night. 0055 Results 0056 Group 1: 100% of patients experienced correction 0030 Presbyopics with hypermetropia (Group 2) were of presbyopia. topically treated with 2% pilocarpine hydrochloride+0.5% 0057 Group 2: 48% of patients abandoned the use of diclofenac sodium, at 6 hr intervals during the daily hours. eyeglasses, 44% only use eyeglasses for near vision with 2 to 0031 Presbyopic patients with phorias (Group 3) were 3 dioptres less than those required before treatment, accord topically treated with 1% pilocarpine hydrochloride at 6 hr ing to their original hypermetropy, and 8% of patients aban intervals during the daily hours, together with an orthoptic doned treatment. treatment directed to stimulate fusion and accommodation 0.058 Group 3: 89.47% of patients abandoned eyeglasses convergence. This orthoptic treatment was performed by and have good near vision, 10.53% did not experience training the patient in the use of an exercising Software, which improvements in their near vision. then the patient used without the need of professional help. 0059 Group 4: 100% of patients had good near vision 3-Minute sessions were carried out daily for a period of 15 without glasses and maintained their ocular hypertension days and were repeated yearly. under control. 0032 Presbyopics patients with glaucoma (Group 4), 0060 Patients who discontinued the treatment experi were topically treated with 2% pilocarpine hydrochloride+0. enced regression of visual sharpness to that before treatment. 5% diclofenac sodium at 6hr intervals during the 24 hours i.e. No worsening of presbyopia was observed, conversely in including nighttime. Regular hypotensive medication used by Some patients accommodation was better than before starting the patients was maintained. treatment. 0033 All patients were monitored after one week treat 1. Ophthalmic compositions
Load more

Recommended publications
  • Comparative Study of the Efficacy of Flunixin, Ketoprofen and Phenylbutazone in Delman Horses with Mild Colic
    Sys Rev Pharm 2020; 11(5): 464 468 A multifaceted review journal in the field of pharmacy E-ISSN 0976-2779 P-ISSN 0975-8453 Comparative Study of the Efficacy of Flunixin, Ketoprofen and Phenylbutazone in Delman Horses with Mild Colic Agus Purnomo1, Arya Pradana Wicaksono2, Dodit Hendrawan2, Muhammad Thohawi Elziyad Purnama3* 1Department of Veterinary Surgery and Radiology, Faculty of Veterinary Medicine, Universitas Gadjah Mada, DI Yogyakarta, 55281, Indonesia 2Postgraduate Studies, Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, 60115, Indonesia 3Department of Veterinary Anatomy, Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, 60115, Indonesia *Corresponding author E-mail: [email protected] Article History: Submitted: 26.02.2020 Revised: 16.04.2020 Accepted: 21.05.2020 ABSTRACT This study aimed to evaluate the efficacy of flunixin, ketoprofen and multiple range test. The results showed a significant alleviation in all phenylbutazone on serum biochemistry, plasma catecholamines and observed variables on Day 13, although the use of various NSAIDs serum cortisol in Delman horses with mild colic. During the study showed no significant difference. period, 32 horses were evaluated due to mild colic. Flunixin, Keywords: serum biochemical, catecholamine, cortisol, colic, NSAIDs ketoprofen, and phenylbutazone were administered intravenously at Correspondence: the recommended dose rates of 1.0; 2.2 and 4.4 mg/kg, respectively. Muhammad Thohawi Elziyad Purnama Administration of the NSAIDs commenced on Day 1 and continued Department of Veterinary Anatomy, Faculty of Veterinary Medicine, every 12 h for 12 days. Blood samples collected between days 2, 5, 9 Universitas Airlangga, Surabaya, 60115, Indonesia and 13 to evaluate AST, ALP, GGT, creatinine, urea, epinephrine, E-mail: [email protected] norepinephrine, and cortisol level.
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
    NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ANALYSIS IN MILK BY QUECHERS AND LC-MS: LOW AND HIGH RESOLUTION DETECTION AND CONFIRMATION APPROACHES A. Rúbies1, L. Guo2, I. Beguiristain1, F. Centrich1, M. Granados2 1. Laboratori Agència de Salut Pública de Barcelona, 2. Departament de Química Analítica - Universitat de Barcelona. * INTRODUCTION NON-STEROIDAL ANTI-INFLAMATORY DRUGS (NSAIDs) Non-steroidal anti-inflammatory drugs (NSAIDs) are used as anti-inflammatory, analgesic and OXICAMS ANTHRANILIC ACID DERIVATIVES ACETIC ACID antipyretic drugs in medicine and veterinary. Their action mechanism is based on the blocking of PROPIONIC ACID DERIVATIVES DERIVATIVES the biosynthesis of prostaglandins. NSAIDs are highly effective and extensively used, but they have some adverse side effects, such as hepatotoxicity, renal disorders or allergic reactions. In the European Union, to assure food safety and protect consumers, maximum residue limits have been established for some authorised NSAIDs in food products. Therefore, high throughput and reliable analytical methodology is required for the effective control of NSAIDs in food from animal Flufenamic acid origin. Liquid chromatography (LC) coupled to mass spectrometry (MS) is currently the technique of choice in confirmatory analysis of NSAIDs residues. We present a new method for the determination of representative NSAIDs in milk based on QuEChERS methodology, LC-MS/MS and UHPLC-HRMS. Meloxicam Ketoprofen Diclofenac EU Maximum Residue Limits (MRLs) Recommended NSAIDs concentrations for NSAIDs in milk.
    [Show full text]
  • In 1977 a Conclusion of the National Association of State Racing Commissioners Veterinary-Chemist Advisory Board Concluded That
    Lawrence R. Soma, VMD, University of Pennsylvania, School of Veterinary Medicine. This review was undertaken at the request of the Racing Medication and Testing Consortium, Medication Advisory Committee. Review: The use of phenylbutazone in the horse This review presents a brief historical prospective of the genesis of regulated medication in the US racing industry of which the non-steroidal anti-inflammatory drug phenylbutazone (PBZ) is the focus. It presents some historical guide posts in the development of the current rules on the use on PBZ by racing jurisdictions in the US. Based on its prevalent use, PBZ still remains a focus of attention. The review examines the information presented in a number of different models used to determine the effects and duration of PBZ in the horse. They include naturally occurring lameness and reversible induced lameness models that directly examine the effects and duration of the administration of various doses of PBZ. The review also examines indirect plasma and tissue models studying the suppression of the release of arachidonic acid- derived mediators of inflammation. The majority of studies suggest an effect of PBZ at 24 hours at 4.4 mg/kg. This reflects and substantiates the opinion of many clinical veterinarians, many of whom will not perform a pre-purchase lameness examination unless the horse is shown to be free of NSAID. This remains the opinion of many Commission Veterinarians in that they wish to examine a horse pre-race without the possibility of a NSAID interfering with the examination and masking possible musculoskeletal conditions. Based on scientific studies, residual effects of PBZ remain at 24 hours following administration.
    [Show full text]
  • Can Cataract Be Prevented?
    Can cataract be JOHN J. HARDING prevented? Abstract The other major drawback of surgery is the risk of complications. In percentage terms the The feasibility of preventing cataract by risk of most complications is small, but given elimination of risk factors or by anti-cataract the enormous number of procedures - about 2 therapy is reviewed. Elimination of the major million per annum in both the United States and risk factors in Western countries would be India, for example - the overall number of even difficult, although it has potential in the serious complications is great. One developing world. Various approaches to drug complication, posterior capsular opacification therapy have been made but ran into (PCO), occurs in up to 50% of patients but in problems. The development of aldose 3 younger patients it affects almost 100%. In reductase inhibitors received by far the many of the countries with the greatest cataract greatest financial support but problems with toxicity were rapidly followed by the collapse problems the equipment to deal with this of the original hypothesis. The case of aspirin, complication is a rarity, a point which is ignored paracetamol and ibuprofen built up more by those advocating greater use of the latest slowly with no encouragement from the Western surgical techniques in developing pharmaceutical industry. Positive results have countries.4 In Nepal the outcome of surgery been achieved in vitro, and in the prevention with intraocular lenses was no better than that of diabetic cataract in rats, as well as the without; and 50% of the impaired vision in identification of an association with a operated eyes was attributed to surgical protective effect against cataract in human complications including PCO.s patients.
    [Show full text]
  • Changes Highlighted Final Version Date of Issue: 23Rd December 2015
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2016 Section A Changed Classes/Guidelines: Changes Highlighted Final Version Date of issue: 23rd December 2015 1 A2B ANTIULCERANTS R1997r2 016 Combinations of specific antiulcerants with anti-infectives against Helicobacter pylori are classified according to the anti-ulcerant substance. For example, proton pump inhibitors in combination with these anti-infectives are classified in A2B2. A2B1 H2 antagonists R2002 Includes, for example, cimetidine, famotidine, nizatidine, ranitidine, roxatidine. Combinations of low dose H2 antagonists with antacids are classified with antacids in A2A6. A2B2 Acid Proton pump inhibitors R2003r2 016 Includes esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole. A2B3 Prostaglandin antiulcerants Includes misoprostol, enprostil. A2B4 Bismuth antiulcerants Includes combinations with antacids. A2B9 All other antiulcerants R2002r2 016 Includes all other products specifically stated to be antiulcerants even when containing antispasmodics (see A3). Combinations of low dose H2 antagonists with antacids are classified with antacids in A2A6. Included are, eg carbenoxolone, gefarnate, pirenzepine, proglumide, sucralfate and sofalcone. Herbal combinations are classified in A2C. In Japan, Korea and Taiwan only, sulpiride and other psycholeptics indicated for ulcer use are also included in this group, whilst in all other countries, these compounds are classified in N5A9. Products containing rebamipide for gastric mucosal protection are classified here. Products containing rebamipide and indicated for dry eye are classified in S1K9. A2C OTHER STOMACH DISORDER PREPARATIONS R1994 Includes herbal preparations and also plain alginic acid. Combinations of antacids with alginic acid are in A2A1. 2 A4 ANTIEMETICS AND ANTINAUSEANTS A4A ANTIEMETICS AND ANTINAUSEANTS R1996 Products indicated for vertigo and Meniere's disease are classified in N7C. Gastroprokinetics are classified in A3F.
    [Show full text]
  • University of Groningen Reflections on Flurbiprofen Eyedrops Van Sorge
    University of Groningen Reflections on flurbiprofen eyedrops van Sorge, Adriaan Alastair IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2002 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): van Sorge, A. A. (2002). Reflections on flurbiprofen eyedrops. s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 25-09-2021 REFLECTIONS ON FLURBIPROFEN EYEDROPS REFLECTIONS ON FLURBIPROFEN EYEDROPS RIJKSUNIVERSITEIT GRONINGEN REFLECTIONS ON FLURBIPROFEN EYEDROPS REFLECTIONS ON FLURBIPROFEN EYEDROPS PROEFSCHRIFT ter verkrijging van het doctoraat in de Wiskunde en Natuurwetenschappen aan de Rijksuniversiteit Groningen, op gezag van de Rector Magnificus, dr. F. Zwarts, in het openbaar te verdedigen op maandag 2 december 2002 om 14.15 uur door Adriaan Alastair van Sorge geboren op 28 oktober 1944 te New Rochelle, New York, USA PROMOTORES Prof.
    [Show full text]
  • Non Steroidal Anti-Inflammatory Drugs
    Non Steroidal Anti‐inflammatory Drugs (NSAIDs) 4 signs of inflammation • Redness ‐ due to local vessel dilatation • Heat ‐ due to local vessel dilatation • Swelling – due to influx of plasma proteins and phagocytic cells into the tissue spaces • Pain – due to local release of enzymes and increased tissue pressure NSAIDs • Cause relief of pain ‐. analgesic • Suppress the signs and symptoms of inflammation. • Exert antipyretic action. • Useful in pain related to inflammation. Esp for superficial/integumental pain . Classification of NSAIDs • Salicylates: aspirin, Sodium salicylate & diflunisal. • Propionic acid derivatives: ibuprofen, ketoprofen, naproxen. • Aryl acetic acid derivatives: diclofenac, ketorolac • Indole derivatives: indomethacin, sulindac • Alkanones: Nabumetone. • Oxicams: piroxicam, tenoxicam Classification of NSAIDs ….. • Anthranilic acid derivatives (fenamates): mefenamic acid and flufenamic acid. • Pyrazolone derivatives: phenylbutazone, oxyphenbutazone, azapropazone (apazone) & dipyrone (novalgine). • Aniline derivatives (analgesic only): paracetamol. Clinical Classif. • Non selective Irreversible COX inhibitors • Non slective Reversible COX inhibitors • Preferential COX 2 inhibitors • 10‐20 fold cox 2 selective • meloxicam, etodolac, nabumetone • Selective COX 2 inhibitors • > 50 fold COX ‐2 selective • Celecoxib, Etoricoxib, Rofecoxib, Valdecoxib • COX 3 Inhibitor? PCM Cyclooxygenase‐1 (COX‐1): -constitutively expressed in wide variety of cells all over the body. -"housekeeping enzyme" -ex. gastric cytoprotection, hemostasis Cyclooxygenase‐2 (COX‐2): -inducible enzyme -dramatically up-regulated during inflammation (10-18X) -constitutive : maintains renal blood flow and renal electrolyte homeostasis Salicylates Acetyl salicylic acid (aspirin). Kinetics: • Well absorbed from the stomach, more from upper small intestine. • Distributed all over the body, 50‐80% bound to plasma protein (albumin). • Metabolized to acetic acid and salicylates (active metabolite). • Salicylate is conjugated with glucuronic acid and glycine. • Excreted by the kidney.
    [Show full text]
  • Composition for Use in Treating and Preventing Inflammation Related Disorder
    (19) TZZ 54¥¥7A_T (11) EP 2 543 357 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 09.01.2013 Bulletin 2013/02 A61K 9/00 (2006.01) A61K 47/36 (2006.01) (21) Application number: 11173000.8 (22) Date of filing: 07.07.2011 (84) Designated Contracting States: (72) Inventor: Lin, Shyh-Shyan AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Taipei (TW) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Becker Kurig Straus Designated Extension States: Bavariastrasse 7 BA ME 80336 München (DE) (71) Applicant: Holy Stone Healthcare Co.,Ltd. Taipei City (TW) (54) Composition for use in treating and preventing inflammation related disorder (57) The presentinvention isrelated to ause fortreat- ease, coeliac disease, conjunctivitis, otitis, allergic rhin- ing and preventing inflammation related disorder of a itis, gingivitis, aphthous ulcer, bronchitis, gastroesopha- composition containing a drug and hyaluronic acid (HA) geal reflux disease (GERD), esophagitis, gastritis, en- or HA mixture, whereas the HA or the HA mixture as a teritis, peptic ulcer, inflammatory bowel disease (IBD), delivery vehicle can be a formulation including at least Crohn’s Disease, irritable bowel syndrome (IBS), intes- two HAs having different average molecular weights. The tinal inflammation or allergy, urethritis, cystitis, vaginitis, composition has been demonstrated to be capable of proctitis, eosinophilic gastroenteritis, or rheumatoid ar- reducing the therapeutic dose of a drug on the treatment thritis. and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary dis- EP 2 543 357 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 2 543 357 A1 2 Description alleviate pain by counteracting the cyclooxygenase (COX) enzyme.
    [Show full text]
  • (Brufen®) Following the Removal of Impacted Third Molar Teeth
    Journal of the Dental Association of SA 38, 739-742 The effect of Ibuprofen (Brufen®) following the removal of impacted third molar teeth Garwood, A.J., Lownie, J.F., Cleaton-Jones, P.E. and Butz, S.J. Division of Maxillo-facial and Oral Surgery, University of the Witwatersrand, and MRC/University of the Wit- watersrand Dental Research Institute, Johannesburg Key words: analgesics; ibuprofen; oral surgery. SUMMARY OPSOMMING Pain, swelling and trismus are common features after the Pyn, swelsel en trismus kom dikwels voor na die chirur- surgical removal of impacted third molar teeth. The pur­ giese verwydering van geimpakteerde derde molare. Die pose of this study was to compare the efficacy and side doel van hierdie ondersoek was om die doeltreffendheid effects o f ibuprofen (Brufen®), a non-steroidal anti-in­ en newe-effekte van ibuprofen (Brufen®), ’n nie-steroi'ed flammatory agent, with that of a control analgesic in a anti-inflammatoriese middel, te vergelyk met die van 'n double blind clinical trial following the removal of im­ kontrole-pyndoder, in ’n dubbel-blinde toets na die chi- pacted third molar teeth. The operative procedure was rurgiese verwydering van bogenoemde tande. Die opera- carried out on 100 patients by one surgeon using a stan­ tiewe prosedure is op 100 pasiente deur een chirurg dardised surgical technique while the survey was carried onderneem, ’n gestandaardiseerde chirurgiese tegniek is out by an independent observer. The results showed that gebruik en die ondersoek is deur ’n onafhanklike waar- ibuprofen compared favourably with the control anal­ nemer gedoen. Die resultate het getoon dat ibuprofen gesic, both o f which produced acceptable analgesia, al­ goed vergelyk met die kontrolepyndoder.
    [Show full text]
  • Pharmaceutical Compositions Containing Non-Steroidal Anti-Inflammatory Drugs
    Europaisches Patentamt J European Patent Office © Publication number: 0 259 047 Office europeen des brevets A1 s EUROPEAN PATENT APPLICATION © Application number: 87307246.6 © int. CIA A61K 45/06 A61 , K 31/60 , A61K 31/405, © Date of filing: 17.0&87 //(A61 K31/60,31 :1 85),(A61 K31/- 405,31:185) ® Priority: 18.08.86 GB 8620073 © Applicant: DELANDALE LABORATORIES LIMITED © Date of publication of application: Delandale House 37 Old Dover Road 09.03.88 Bulletin 88/10 Canterbury Kent CT1 3JF(GB) © Designated Contracting States: @ inventor: Trigger, David John AT BE CH DE ES FR GB GR IT LI LU NL SE 74 Mountbatten Way Brabourne Lees Ashford Kent TN25 6PU(GB) © Representative: Paget, Hugh Charles Edward etal MEWBURN ELUS & CO. 2/3 Cursitor Street London EC4A 1BQ(GB) © Pharmaceutical compositions containing non-steroidal anti-Inflammatory drugs. © A pharmaceutical composition for treating an inflammatory condition contains a non-steroidal anti-inflam- matory drug (NSAID) and a physiologically acceptable aromatic hydroxysulphonic acid. The two components may be for simultaneousr separate or sequential use. Administration of the two components, for example of aspirin with ethamsylate, reduces the damage which the NSAID does to the gastrointestinal tract while having no deleterious effect on the anti-inflammatory activity. s in cm Q. LU Xerox Copy Centre 0 259 047 PHARMACEUTICAL COMPOSITIONS CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS The present invention relates to pharmaceutical compositions containing aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs). The non-steroidal anti-inflammatory drugs are a group of compounds which inhibit the biosynthesis of prostaglandins.
    [Show full text]
  • 2018/CM05 Horse: CHIRO D' ANDRUER
    DECISION of the FEI TRIBUNAL dated 23 October 2018 Positive Controlled Medication Case No.: 2018/CM05 Horse: CHIRO D’ ANDRUERE FEI Passport No: 103VS23/UAE Person Responsible/NF/ID: Thani Mohd Ahmad AL MARRI/UAE/10113330 Event/ID: CEI1* 80 – Dubai (UAE)/2018_CI_0523_E_S_02_01 Date: 1 February 2018 Prohibited Substances: Phenylbutazone, Oxyphenbutazone, Dexamethasone and Diclofenac. I. COMPOSITION OF PANEL Mr. Henrik Arle (FIN), one member panel II. SUMMARY OF THE FACTS 1. Memorandum of case: By Legal Department. 2. Summary information provided by Person Responsible (PR): The FEI Tribunal duly took into consideration all evidence, submissions and documents presented in the case file, as also made available by and to the PR. 3. Oral hearing: none. III. DESCRIPTION OF THE CASE FROM THE LEGAL VIEWPOINT 1. Articles of the Statutes/Regulations which are applicable: Statutes 23rd edition, effective 29 April 2015 (“Statutes”), Arts. 1.4, 38 and 39. General Regulations, 23rd edition, 1 January 2009, updates effective 1 January 2018, Arts. 118, 143.1, 161, 168 and 169 (“GRs”). Page 1 of 11 Internal Regulations of the FEI Tribunal, 2nd edition, 1 January 2012, and Internal Regulations of the FEI Tribunal, 3rd Edition, 2 March 2018 (Part I – 3.) (“IRs”). FEI Equine Anti-Doping and Controlled Medication Regulations ("EADCMRs"), 2nd edition, effective 1 January 2018. FEI Controlled Medication Regulations ("ECM Rules"), 2nd edition, effective 1 January 2018. Veterinary Regulations (“VRs”), 14th edition 2018, effective 1 January 2018, Art. 1055 and seq. FEI Code of Conduct for the Welfare of the Horse. 2. Person Responsible: Mr. Thani Mohd Ahmad Al Marri. 3.
    [Show full text]
  • Methods Research Report: Empirical Evidence of Associations Between
    Methods Research Report Empirical Evidence of Associations Between Trial Quality and Effect Size Methods Research Report Empirical Evidence of Associations Between Trial Quality and Effect Size Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 http://www.ahrq.gov Contract No. HHSA 290-2007-10062-I Prepared by: Southern California Evidence-based Practice Center Santa Monica, CA Investigators: Susanne Hempel, Ph.D. Marika J. Suttorp, M.S. Jeremy N.V. Miles, Ph.D. Zhen Wang, M.S. Margaret Maglione, M.P.P. Sally Morton, Ph.D. Breanne Johnsen, B.A. Diane Valentine, J.D. Paul G. Shekelle, M.D., Ph.D. AHRQ Publication No. 11-EHC045-EF June 2011 This report is based on research conducted by the Southern California Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10062-I). The findings and conclusions in this document are those of the author(s), who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment.
    [Show full text]